$3.99
1.24% yesterday
Nasdaq, Sep 24, 10:15 pm CET
ISIN
US38246G1085
Symbol
GDRX

GoodRx Holdings Stock News

Negative
Seeking Alpha
9 days ago
GoodRx offers compelling value after a ~50% stock decline over the past 12 months, trading at just 6.1x FY25 adjusted EBITDA despite recent execution challenges. A new Novo Nordisk partnership for Ozempic and Wegovy discounts could attract new users and offset recent guidance cuts and Rite Aid-related headwinds. The company cut its revenue and adjusted EBITDA outlook for FY25, which was widely ...
Neutral
Business Wire
23 days ago
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., is riding into new creative territory with the launch of The Savings Wrangler, a groundbreaking brand campaign that aims to bring the company's mission to life in an unforgettable way. Designed to deepen cultural relevance and brand resonance, the campaign introduces a lasso-wi...
Positive
Invezz
about one month ago
Goodrx Holdings Inc (NASDAQ: GDRX) closed roughly 50% higher on August 18th after Bagsværd-headquartered Novo Nordisk (NYSE: NVO) announced a GLP-1 partnership with the healthcare platform. According to the companies' joint press release today, “all strengths of Ozempic and Wegovy are now available to eligible self-paying patients for $499/month through GoodRx.
Positive
Seeking Alpha
about one month ago
GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing, driving a 30% stock surge and validating its business model. Pharma Manufacturer Solutions is growing 30%+ annually, boosting profitability and positioning GoodRx as a key player as drug pricing shifts to point-of-sale affordability. Despite headwinds like Rite Aid's bankruptcy an...
Positive
Fast Company
about one month ago
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy.
Positive
Proactive Investors
about one month ago
Novo Nordisk (NYSE:NVO) shares moved higher on Monday after it was announced that US patients can access its diabetes drug Ozempic at a cheaper price through several platforms, expanding access to the therapy for those who do not have insurance coverage.  Patients can pay $499 in cash per month through the drug's website, Novo Nordisk's patient assistance program, the company's direct-to-consum...
Positive
Barrons
about one month ago
GoodRx announces a collaboration with Novo Nordisk to make Ozempic cheaper for self-paying patients.
Neutral
Business Wire
about one month ago
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the pric...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today